Search Results
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.
To see how ziltivekimab taken once monthly versus placebo, both added to standard of care, in reducing the risk of cardiovascular death and heart failure events in participants with heart failure iwht mildly reduced or preserved ejection fraction and systemic inflammation.
Return for on site visits 14 times, participate in 6 phone calls, complete questionnaires, blood samples taken at each on-site visit, electrocardiogram completed on 5 visits, injection of study medication.
approximatley $1,120
age 18 years or above
unstable medical therapy for heart failure
active hepatitis C
pregnant females or females not using effective contraceptive
LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study (LUX-Dx TRENDS)
The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer added heart failure diagnostic features. Patients will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell the study doctor if any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if they have been treated with an IV medication for heart failure in the emergency room, urgent care or clinic.
The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer addedheart failure diagnostic features. You will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell your study doctor if you have any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if you have been treated with an IV medication for your heart failure in the emergency room, urgent care or your clinic.
$250
>18 years of age
Undergone a heart transplant
Currently enrolled in another investigational study
Pregnant or plans to become pregnant
Diagnosed with amyloidosis or hypertrophic cardiomyopathy
The effects of creatine supplementation on neurocognitive function of college students of differing levels and types of physical activity
This study design is a survey that collects information about students' active level and supplement use, with an emphasis on creatine. The difference between contact and non-contact athletes will be examined, in addition to people who are considered inactive/low activity. This will help provide information of how physical activity related supplementation use affects cognition in different populations, with varying amounts of neurotrauma.
All participants will complete a digital survey that provides information about their dietary supplementation and physical activity habits. As part of the survey, participants will be allowed to indicate their interest and availability to come to a laboratory setting to complete a brief batter of neurocognitive tests.
Has had concussion in last 3 months
Intraparticipant speaking rate differences within and across sessions
The purpose of this study is to assess if healthy adults speak at a consistent speaking rate when asked to read a standard passage or answer an open ended prompt.
There will be 2 visits that each take approximately 20 minutes. We will meet in person or via Zoom. At each visit you will be asked to read three paragraphs and answer some open ended questions/prompts.
English-speaking
Hearing and cognition within functional limits to complete speaking tasks
History of neurologic disease, injury, or event including traumatic brain injury, stroke, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, etc.
Exploring the Concreteness Effect in Expressive and Receptive Language Measures in Healthy Aging as a Comparison for Persons with Aphasia
The concreteness effect is the finding that individuals are faster and more efficient at processing concrete words (e.g., "dog") than abstract words (e.g., "wisdom"). The study will investigate the presence and strength of the concreteness effect in neurologically intact older adults. This data will be used as a control comparison for a group of people with aphasia, a language disorder that commonly results from left hemisphere stroke.
Participants will be asked to complete language and cognition tests that measure attention, memory, problem solving, and language processing on the computer. Participants will be asked to complete two Zoom sessions, each lasting approximately 1.5 hours.
30
At least a high school education
40 years of age or older
Access to device with keyboard and internet connection to participate in Zoom sessions
Below 40 years of age
PSCI 22-132 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
The purpose of this voluntary research study is to evaluate potential new anticancer to treat people with tumors similar to yours. This study will provide information about the safety, the ability of your body to accept the study drug(s), the amount of study drug(s) and/or break-down products in your blood, and your body’s reaction to the study drug(s). Participants will be required to take study medication, have blood drawn, and have imaging tests such as CT, MRI, ECG, MUGA, ECHO, and bone scans.
Participants in the expansion stage will receive study treatment, imaging exams (ECHO, MUGA, ECG, CT, MRI, bone scans), blood draws, tumor assessments, and tumor tissue samples.
For all Expansion Cohorts except Cohort 3 (mCRPC): Measurable disease per RECIST
For Expansion Cohorts only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.
Recovery to baseline or ≤ Grade 1 CTCAE v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
Age 18 years or older on the day of consent
Cohort 2 (ccRCC 2L), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC, 2L+), and Cohort 10 (CRC, 2L+): Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.
Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before first dose of study treatment.
Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
Sound Symbolism and Aphasia
Sound symbolism is the idea that the sound of a word alone can convey its meaning. Aphasia is a language impairment, occurring most often as a result of a stroke. There is some evidence that sound-symbolic language is preserved in stroke patients. Studies in this protocol will investigate the extent to which this is so, and whether sound-symbolic language could be a rehabilitation strategy for aphasia.
We will ask you to listen to real words and non-words and make judgements about them. We may also ask you to complete some tests of language ability. The total time commitment may be up to four hours but will be split into two sessions.
Amount varies depending on the study
Must have English as your first language
Must have normal or corrected-to-normal vision
Must report normal hearing
May have a recent diagnosis of aphasia following a stroke
Bilingual persons may be excluded from some studies
Minors under the age of 18
Neurobehavioral mechanisms of social and non-social risky decision making.
The purpose of this study is to understand the neural and behavioral mechanisms subserving social and non-social risky decision making.
There will be one in-person lab visit where you will play a decision-making game, while having an fMRI scan.
$31.25
Able to read and speak English
Normal to corrected vision in order to see a computer screen clearly
No history of head injury
No MRI contraindications
History of head injury
Had an event where loss of consciousness > 10 minutes
Weighs more than 300 pounds
Does not read and speak English
A PHASE 1B OPEN-LABEL/ PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY FOR PHARMACODYNAMIC ACTIVITY, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF KAN-101 IN PATIENTS WITH CELIAC DISEASE-A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease
At this time, there is no treatment available for celiac disease diagnosis. The study is designed to test safety, tolerability and pharmacokinetics of KAN-101 to treat celiac disease diagnosis. We will participate only in the Part B study portion. Part B is a Phase 2, double-blind, placebo-controlled, parallel design study to characterize the biomarker response (plasma IL-2) in peripheral blood following gluten challenge, safety, tolerability, and pharmacokinetics (how does drug move in the body) of KAN-101 in adult participants (18 to 70 years inclusive) with histology-confirmed celiac disease. Participants will be randomized 1:1:1:1, where one arm is placebo, and other arms are different drug doses. The study consists of a screening period to determine eligibility to participate, a run-in phase where participants are gluten-challenged for one day, a treatment phase where participants will receive a seven-days treatment, and observation period lasting 358 days where participants will have a post-dose gluten challenge on Day 15, and three other time-points. The study aims to enroll 120 subjects across all sites. Participants will be asked to come for the clinic visit, to have gluten challenged done in the clinic, and treatment infusions in the clinic. There are two follow-up visits planned. The participants will have required EGD w/biopsy, and will be offered optional EGD biopsy study, that collects specimens at two time points. All participants will have a blood work done to access eligibility for participation, and to test for drug PK and biomarkers in the response of the treatment. They will also have EKG and physical examinations, vital signs checked during the clinic visits. They will complete questions for patient reported symptoms. Eligible women participants will be tested for pregnancy, and contraception will be discussed for both male and female participants.
Participants will be asked to come to the clinic visits for the screening, gluten challenge, treatment visits and follow up. During the visits, participants will have blood tests done to determine eligibility for the study, or the test how the drug moves through the body and whether it works to dampen the celiac disease symptoms. The patients will have EGD with biopsies procedure done in the endoscopy suite, and they will be offered optional biopsies study. The gluten challenge will consist of drinking a glass of water containing 9g pre-prepared gluten challenge mix. The participants will be observed for four hours. The treatment is done via infusion in the clinic over 30-minutes,and observed for four hours after that. The participants will have to come in for three treatment visits within seven days (days 1, 4, and 7).
$975
positive celiac serology and histology
followed gluten free diet for more than a year
have wheat allergy
have hypersensitivity to gluten
active GI disease
have Type 1 diabetes
PSCI 23-099 NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancerand an Oncotype Recurrence Score ≤ 25 (OFSET)
To determine if chemotherapy added to ovarian suppression and endocrine therapy is better than endocrine therapy and ovarian supression alone.
Subjects will be required to keep all study appointments, take the medications as required, have an annual mammogram, inform the study of any over the counter medications they may be taking.
Patients must be premenopausal
The patient must have an ECOG performance status of ≤ 2
Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.
Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.
pT4 tumors, including inflammatory breast cancer.
History of ipsilateral or contralateral invasive breast cancer.
Life expectancy of < 10 years due to co-morbid conditions in the opinion of the investigator.
PSCI 22-142 A Randomized, Open-label, Phase 3 Study of Sacituzumab GovitecanVersus Treatment of Physician’s Choice in Patients With HormoneReceptor-Positive (HR+)/Human Epidermal Growth Factor Receptor2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
This trial is to compare the effects of sacituzumab govitecan versus physician's choice in the treatment of breast cancer
Potential participants will be expected to come to all study visits, complete questionnaires, take the medication as prescribed by the study doctor, report any changes in medications of symptoms while on the trial.
Must have adequate tumor tissue sample preferably from locally recurrent or metastatic site, either in a formalin-fixed, paraffin-embedded block or newly sectioned, unstained slides for HER2 status and other biomarker assessments.
Documented evidence of HR+ metastatic breast cancer (mBC)
Documented evidence of HER2− status
Documented PD by computed tomography (CT) or magnetic resonance imaging
Previously HER2+
Locally advanced mBC (Stage IIIc) in patients who are candidates for curative intent therapy at the time of study enrollment
Current enrollment in another clinical study
Treatment with definitive radiation within 2 weeks prior to the first dose of study drug
A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
This study is a placebo-controlled study testing the effectiveness and safety of a new drug (izokibep) in adults with hidradenitis suppurativa (HS). HS is a condition where painful skin lesions occur, most often in places on the body where there is friction (ex: armpits, under the breasts, buttocks, and groin). These lesions can drain and scar and will often reoccur.
For this study, participants will come to the study site about 17 times over approximately 59 weeks. During these visits, there will information about medical history and medications collected as well as demographic information, physical and skin exams, vital signs, blood and urine lab testing, ECGs, a chest x-ray, questionnaires, and a daily diary.
HS in at least 2 body sites
Willingness to follow study rules and instructions of study staff
Chronic pain not associated with HS
History of HIV
Early Identification in Older Adults of Risks to Sleep Health, Movement, and Cognition Using Ecological Methods
This proposal is a prospective study in which we will collect both subjective and objective quantitative data from older adults residing in independent living retirement communities, microlongitudinally (~1wk). Comprehensive measures of sleep health, cognition, and movement will be collected at community residences. The first phase of this project will recruit local, State College area adults over 70 residing in independent living facilities (e.g., Foxdale Village and The Village at Penn State). A second phase of data collection will extend to community-based older adults in rural parts of Centre and nearby counties.With this prospective, microlongitudinal information we will evaluate the characteristics of sleep predictive of daytime cognitive and neurobehavioral function and use those conclusions to inform nonpharmacologic, preventative interventions for older adults.
After consent, there will be 6 study visits at either Penn State University Park campus or at the participant's personal residence. Study participation lasts about 1 week.Participants wear non-invasive ambulatory watch-like activity monitors throughout (both day and night) the week. Participants complete electronic surveys and cognitive tests 6 times daily, with additional surveys at study conclusion.Sleep and daytime brain and heart activity are recorded (without video) using non-invasive clinical-type wire sensors applied to the face, head, and chest. Wires are worn on the face, head, and chest throughout the first two study nights. Wires are worn on the head and chest throughout the first two study days. There is not a sleep intervention in this study. We are collecting data about the typical sleep health of older adults and its relation to cognitive health.
$350
Resident of PA, Centre County region
Living without functional assistance
Able to walk unassisted for at least 5min
Evidence of cognitive impairment (will be tested)
Genomic Profiling of Urothelial Cancers Study
The objective of this protocol is to study urothelial cancer with detailed health history, tumor and/or normal tissues available for genomic sequencing to study cancers in the bladder, upper urinary tract, and urethra. There will be 3 groups of subjects in this study:1)Urothelial cancer patients receiving care at Penn State Health2)Relatives of patients with urothelial cancer3)High risk-cohort of individuals with family history of urothelial cancers or inherited cancer syndromes (such as Lynch syndrome) candidates for urothelial cancer screening evaluation
All subjects will be asked to fill out questionnaires to assess risk factors for urinary cancer and document family history of cancer. You will be asked to provide a blood sample and urine sample for genetic testing. Patients with urothelial cancer will be asked to allow us to test leftover tissue from a past or future biopsy to test cancer and/or normal cells for certain mutations. We may also ask you for a saliva sample, cheek swab, skin biopsy, or nail clippings for comparison.
personal or family history of bladder cancer
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study
The purpose of this study is to find out if the experimental drug (brensocatib) improves symptoms of Chronic Rhinosinusitis Without Nasal Polyps and is safe. Study treatments include the study drug and mometasone furoate nasal spray (referred to as mometasone). The study drug will either be brensocatib (“active” drug that contains “real” drug) or placebo (looks like brensocatib but does not have any “real” drug in it). Mometasone will be taken by all participants throughout the study as routine care.
If you choose to participate in the study, the following main activities and procedures are required.•Complete questionnaires asking about your chronic rhinosinusitis symptoms and quality of life•Measure the amount of air you can breathe in through both sides of your nose (nasal airflow)•Electrocardiogram (ECG) and vital signs•Physical examination, including examinations of your mouth and skin•Provide blood and urine samples•Sinus computed tomography (CT) scan•Attend 9 study visits•Nasal endoscopy
Unknown at this time
Participants who have at least a 12-week history before Screening Visit of Chronic Rhinosinusitis without nasal polyps
Received a course of antibiotics or steroids to treat symptoms of Chronic Rhinosinusitis within 1 year or previous surgery for Chronic Rhinosinusitis
Diagnosis of Cystic Fibrosis or Primary Ciliary Dyskinesia
Scheduled sinus surgery at any time during the study or have had nasal surgery within 4 weeks of the first study visit
Participants with seasonal allergic rhinitis whose symptoms occur during the treatment period of the study
Current smoker
Pilot study examining adherence to and efficacy of the quitSTART smoking cessation smartphone application
The goal of this pilot study is to collect preliminary information about the effectiveness of a smoking cessation app called quitSTART, which is a product of Smokefree.gov created by the Tobacco Control Research Branch at the National Cancer Institute. The app is available to the public for download at no cost. The aims of the project are: 1) to measure how participants respond to the app and how they use it during an attempt to quit smoking; and 2) receptivity and adherence rates to the app; 2) to examine whether participants reduce or discontinue smoking while using the app.
The study is designed to test the efficacy of a smoking cessation smartphone app and has three parts. For the first part, participants are asked to watch an orientation video about the study, fill out questionnaires, and watch a video tutorial explaining how to use a smartphone app. Then, for the second part of the study, participants are asked to use the smoking cessation app to help them with their quit attempt for 30 days. Finally, for the third part of the study, participants are asked to complete an exit survey about their experience using the app after 30 days.
$20
Must smoke cigarettes everyday
Must own and regularly use a smartphone
Must be planning a quit attempt within the next month
Must be willing to use a smartphone app to assist them during a quit attempt
Previously used the quitSTART smartphone app
Sex and race differences in exercise pressor reflex under blood flow restriction condition
The purpose of this voluntary research study is to test the effects of exercise on reduction in blood flow to exercising muscle.
You will be asked to participate in one visit to perform handgrip exercise and foot exercises with, and without a blood pressure cuff inflated on your arm and leg. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate, blood flow and muscle oxygenation.
You will receive $25 per hour for your participation in this research study
All races and ethnicities welcome
Are fluent in written and spoken English
Healthy status as defined by history and physical
blood pressure that is within a safe range (<150/100)
Pregnant or nursing woman
Current smoker
Any chronic diseases (heart, lung, neuromuscular disease or diabetes)
High blood pressure
Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG)
This study is being done to learn if a vaccine made in the laboratory from your tumor and your immune cells is safe to give to you to treat your tumor. It is believed that the body’s immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use your tumor and immune cells from your blood to make a vaccine that we hope will stimulate your T-cells to kill tumor cells and leave your normal cells alone.
You will need routine (standard of care) testing for your tumor, as well as research tests and procedures including further analysis of your tumor sample, generation and review of a personalized genetic report, and procedures to collect certain cells for different infusions and creation of specialized cellular vaccines. You will then be offered and placed on a treatment plan. As a subject in this study you will remain in this study until you complete vaccine therapy as long as you have no disease progression or unless you need to come off study for another reason.
For Neuroblastoma must be >12 months and ≤ 30 years of age
For DIPG must be ≥ 3 years and ≤ 30 years of age
Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection
A Phase 3 Open-label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics, and Efficacy ofCSL312 (Garadacimab) in the Prophylactic Treatment ofHereditary Angioedema in Pediatric Subjects 2 to 11 Years ofAge
This is a voluntary research study that will help us see if the study medication, CSL312, is safe to use in children 2-11 years of age. The research study will also help to see if the medication works to prevent HAE attacks in this age group.
Attend 8 to 9 visits to the study center. Provide personal information about the child participating in the study and complete electronic diaries (eDiaries). The child participating in the study will have physical exams, vital signs, and blood/urine tests completed. The study medication will be given via injection.
Diagnosis of Hereditary Angioedema Type 1 or Type 2
Two or more Hereditary Angioedema attacks within the last 6 months or the 6 months before starting a preventative medication
Receiving any other experimental drug
Diagnosis of any other form of angioedema
Emotion dynamics and alcohol use in NIAAA-defined recovery from alcohol use disorder
This study uses a baseline assessment and 28 days of ecological momentary assessment to examine the association of emotion dynamics to craving and alcohol use among people in the first year of cessation of heavy drinking and remission from DSM-5 AUD.
There will be one in person visit. Participants will be asked to complete baseline questionnaires. After the baseline assessment, participants will complete 28 days of daily diary questions on their cell phone. A prompt will be sent to the phone 3 times per day. It should take 5 minutes (15 minutes total/day) to complete the questions.
189
Have a history of a previous (AUD) in the past year
Live within commuting distance of the Penn State Clinical Research Center
Bipolar disorder
Cognitive impairment
Active drug use disorder other than nicotine or cannabis dependence
Lack of sufficient familiarity with the English language to comprehend recruitment and consent procedures
Impact of fermented pulses on inflammation and the gut microbiota
The purpose of this study is to investigate whether fermenting pulse foods (e.g. beans, chickpeas, lentils, peas, etc.) changes their effects on the gut microbiome and inflammation. Participants will eat provided meals of either fermented or unfermented pulses, providing blood and fecal samples at the beginning of the study and after two weeks of eating meals containing each of the pulse types.
The study lasts 8 weeks. 2 weeks where you do not consume any of the test food (pulses such as chickpeas, lentils, peas or beans), 2 weeks of consuming the first type of the provided meals, 2 weeks without consuming any of the test foods, 2 weeks consuming the second type of provided meals. There will be five in person visits, one at the beginning to provide consent and then one at the end of each 2 week section. At three of these visits a fecal sample will be collected, blood will be drawn and a dietary survey completed.
300
18-65
BMI >24.9
Taking any medication for diabetes or weight management
Pregnant
Allergies to meal components
Effect of color, lighting, and music on visual perception, cognition, and emotion
To comprehensively examine the psychological effects of abstract lighting patterns on individuals' emotional states, cognitive performance, and overall well-being. Secondly, the study aims to explore the intriguing connection between music-color synesthesia and the perception of lighting conditions.
Participants will complete cognitive tests and subjective evaluations
normal color vision
adults between 18 and 40
metal allergy
Infection threat and social decision-making using fMRI
The purpose of this study is to test how social decisions are affected by possible risk of infection. We aim to examine the neural and behavioral mechanisms underlying how choices in a risky social decision-making situation can be influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.
Participants will come to the research site for a one-time visit. They will complete brief questionnaires, followed by playing a social decision-making game while undergoing fMRI scanning.
$35.42
English speaking
Does not suffer from claustrophobia
Does not have contraindications to MRI scanning
Does not weigh more than 300 pounds
Cannot speak English
Suffers from claustrophobia
Has contraindications to MRI scanning
Weighs more than 300 pounds
Lighting, familiarity, decision making and risk taking
The effect of familiarity of an space on visual and lighting perceptions, and the effect of lighting conditions on risk taking and decision making will be investigated
Participants will wear sensors and complete survey that consists of decision making questions and subjective evaluations of architectural spaces.
Good visual acuity
Metal allergy
PSCI 23-008: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status ACR-368-201/GOG-3082
This trial will be looking at patients with OncoSignature positive and negative tumors using the treatment of the study drug in combination with ultra low dose gemcitabine.
If you are in Arm 1, you will receive ACR-368 as a single intravenous (in the vein) infusion over approximately 60 minutes twice during a 4-week period, on Days 1 and 15. This entire 4-week period is called a cycle. If you are in Arm 2, you will receive gemcitabine and ACR-368 as two separate intravenous (in the vein) infusions. The gemcitabine infusion will last approximately 30 minutes and the ACR-368 infusion will last approximately 60 minutes. •Biopsy Sample and OncoSignature® Status•Archived Tumor Sample and Genomic Information•Physical Exam•Pregnancy Test if applicable•Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan•Blood Sampling for CA-125 (Ovarian carcinoma only)
Subject must have histologically confirmed, locally advanced (ie, not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
Subject must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator)
Subject must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after signed informed consent.
Subject must have an estimated life expectancy of longer than 3 months.
Subject has a history of clinically meaningful coagulopathy, bleeding diathesis.
Subject had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.
Subject with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent).
Subject has taken a prior cell cycle CHK1 inhibitor, including ACR-368.
Personality Pathology in Youth
In this study, we hope to better understand the neural mechanisms underlying risk for personality disorders in adolescent youth. Understanding who is at risk for personality disorders early in development is important in order to develop preventative interventions.
Youth participants and their parent will be required to attend one in-person visit at our lab in Hershey, PA where youth participants will complete two computer tasks while EEG data are collected. Youth participants will also complete questionnaires and a peer-interaction task with another peer their age. Parents will complete questionnaires and an interaction task with their child. Youth participants will complete remote surveys via a survey app for two weeks after the visit. This study includes 4 follow-up appointments (once every 6 months) which can be completed in-person or remotely via a Microsoft Teams meeting. These follow-up appointments will consist of a parent-child interaction task and surveys for parent and youth participants.
$300
Current or past history of a mental health disorder OR no history of mental health disorder
Fluent in English
Youth or parent not fluent in English
Youth with intellectual or development disabilities
Youth with schizophrenia, bipolar disorder, or other psychotic disorders
The impact of structural racism and discrimination on chronic pain in Black or African American older adults: Biopsychosocial mechanisms
This study is trying to understand more about factors that cause pain in people who have had experiences of discrimination.
Study Requirements:-Two visits - each ~3 hours to the Milton S. Hershey Medical Center-Visit 1: computer questionnaires, sensory testing, mobility testing, blood draw-Visit 2: questionnaires, 1-hr MRI with painful but tolerable heat and sounds-At home questionnaires online between visits or added to second visit -Video and vital sign monitoring during some parts-Option to wear a smartwatch between visits for additional compensationStudy Compensation:-$175 with the option of up to $225-Visit 1: $100-Visit 2: $75-Smartwatch option: $50-Reimbursement for parking, transportation, or free ride via Uber Health-Souvenir copy of your brain scan
$225 + $25/visit transportation
Age 45 and up
Identify as Black or African American
Able to perform experimental tasks
Speak, read, and understand English
Metal in body that is not safe for MRI
Previous abnormal MRI
Pregnancy
Using grip force as a measure of fear in humans during a robot guided haunted house scenario
The objectives of the study are to determine whether grip force is related to participants’ fear and whether touch feedback from a robot can effectively communicate risk in a simulated high stress environment. We hypothesize that grip force increases in stressful situations like walking through a haunted house. Like in a real haunted house, people often find comfort in holding hands with someone as they walk through. In this study, a participant walks through a virtual haunted house.
There will be one in person visit. Participant will wear VR equipment and chest heart rate monitor. They will hold a virtual robot's hand and walk through a VR haunted house environment until it is over. They will then answer a brief survey.
15
Must not be suffering from anxiety disorders and/or panic attacks.
Must not be suffering from any known heart conditions.
Must not, to your knowledge, be prone to nausea when experiencing VR
Motion sickness caused by VR
Heart problems
Anxiety disorder
prone to nausea in VR
Investigating Post-Pandemic Impacts on the Mobility of Transportation Disadvantaged Groups
In this study, we're investigating how the COVID-19 pandemic has influenced the way people who face challenges in transportation—perhaps due to limited access or resources—get around. We're curious about any changes they made during the pandemic, like using different modes of transportation or adjusting their travel habits. Additionally, we're exploring whether these changes might stick around even after the pandemic. It's all about understanding the impact of the pandemic on the travel choices of those who already face transportation difficulties and what this might mean for the future.
There will be a questionnaire that should take approximately 15 minutes to complete.
Do not own or lease private vehicle
Disability that impacts mobility
Rely on government assistance (state or federal)
Private vehicle owners
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients with Nonalcoholic Steatohepatitis
This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)
El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements & surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.
Evidence of NASH
Posission of a Smart Phone
Active or recent participation in exercise training program within the last 90 years
Active or recent weight-loss supplement use within the last 90 days
Active illicit substance use
Cancer that is active